Share
.webp)
.webp)
.webp)
.webp)
Sonia Quaratino
Engitix Ltd., a biotechnology company developing extracellular matrix (ECM)-based discovery platforms for oncology, fibrosis and fibro-inflammatory diseases, has appointed Sonia Quaratino, MD, PhD, as Executive Vice President and Chief Medical Officer in a newly created role.
Dr. Quaratino brings more than 35 years of experience spanning immunology and oncology research, clinical development and strategic leadership across biotechnology, pharmaceutical companies and academia. Her expertise includes chronic inflammatory diseases, autoimmunity and oncology, with a focus on the relationship between inflammation, fibrosis and cancer.
She has served as an independent non-executive Director on Engitix’s Board since 2023. In her new role, Dr. Quaratino will oversee the company’s clinical and medical strategy as Engitix advances its ECM-targeting therapeutic pipeline toward clinical development.
Most recently, she served as Executive Vice President and Chief Medical Officer at Innate Pharma. Previously, she was Chief Medical Officer of Georgiamune and Kymab, where she helped guide both companies through the transition from preclinical research into clinical-stage development.
At Kymab, her strategic leadership contributed to the development of the company’s pipeline, culminating in its acquisition by Sanofi for an upfront $1.1 billion in 2021.
Earlier in her career, Dr. Quaratino held senior roles at Novartis and Merck KGaA following an academic career that included serving as Professor of Immunology at the University of Southampton. She also serves on the Board of Advisors of Pureos Bioventures and has held previous non-executive board positions.
Dr. Quaratino earned her medical degree and doctorate in Haematology-Oncology from the University of Palermo and a PhD in Immunology from Imperial College London.
